A Phase 2 interventional study of SAR441344 IV and placebo IV in Multiple Sclerosis, sponsored by Sanofi. Active, not recruiting at 37 sites in 10 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Multiple Sclerosis by Sanofi — 3 open to participants now, 6 under way, 4 of them phase 3. Multiple Sclerosis · Sanofi.
Among the 44 studies in Multiple Sclerosis by Sanofi, this one is the 25th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2021, is one of 13 in phase 2, and was the 35th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →3 of the 44 studies in Multiple Sclerosis by Sanofi are open now, in 8 countries. Recruiting first, the newest first:
Sanofi · Sites in United Arab Emirates
Ages 18+
Sanofi · Sites in United States, Belgium, Brazil and 4 more countries
Ages 18–60
Sanofi
Ages 18–60
By country, each count listing its studies:
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 166 across the 41 interventional studies, 220 across the 3 observational. Of the 38 that completed or were terminated, 23 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
2 of the studies in Multiple Sclerosis by Sanofi that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Multiple Sclerosis by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To determine the efficacy of SAR441344 as measured by reduction of the number of new active brain lesions
Secondary Objective:
The duration of each participant will be no longer than 320weeks in both parts of the study, including 4 weeks of screening, at maximum 292 weeks of treatment and 24 weeks of follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SAR441344 IV
Drug: SAR441344 IV · Drug: MRI contrast-enhancing preparations
Placebo IV
Drug: placebo IV · Drug: MRI contrast-enhancing preparations
SAR441344 SC
Drug: SAR441344 SC · Drug: MRI contrast-enhancing preparations
Placebo SC
Drug: placebo SC · Drug: MRI contrast-enhancing preparations
Pharmaceutical form: Solution Route of administration: IV infusion
Pharmaceutical form: Solution Route of administration: IV infusion
Pharmaceutical form: Solution Route of administration: SC injection
Pharmaceutical form: Solution Route of administration: SC injection
gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem
Mean Number of New Gadolinium (Gd)-Enhancing T1--Hyperintense (GdE T1) Lesions at Week 12 Relative to Week 8 as Measured by Brain Magnetic Resonance Imaging (MRI)
Cranial (brain) MRI was performed to identify number of new GdE T1-hyperintense lesions at Week 12 relative to Week 8 MRI. Central review was used to identify new GdE T1 lesions not present at the previous MRI scans.
Time frame: Week 8 and Week 12
Mean Number of New or Enlarging T2 Lesions at Week 12 Relative to Week 8
Cranial (brain) MRI was performed to identify number of new or enlarging T2 lesions at Week 12 relative to Week 8.
Time frame: Week 8 and Week 12
Mean Total Number of GdE T1 Lesions at Week 12
Cranial (brain) MRI was performed to identify total number of GdE T1 lesions at Week 12.
Time frame: Baseline (Day 1) and Week 12
Double-Blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.
Time frame: From first dose of study drug (Day 1) up to 12 weeks (DB TE period)
Double-Blind Period: Number of Participant With Anti-Drug Antibodies (ADAs) Against SAR441344
Blood samples were collected at specified timepoints to assess the presence of ADAs against SAR441344. Treatment-emergent ADA was defined as at least 1 treatment-induced/boosted ADA. Treatment-induced ADA was defined as ADA that developed during the TE period and without pre-existing ADA (including participants without pre-treatment samples). Treatment-boosted ADA was defined as pre-existing ADA that was boosted during the TE period to a significant higher titer than the baseline. Number of participants with treatment-emergent ADA are presented.
Time frame: From first dose of study drug (Day 1) up to 12 weeks (DB TE period)
Maximum Plasma Concentration (Cmax) of SAR441344
Blood samples were collected at the specified timepoints for the assessment of Cmax. Cmax was assessed by a Bayesian approach using the population pharmacokinetic (PK) model.
Time frame: After dose on Day 1 (first dose) and Weeks 8 (IV arm) and 10 (SC arm) (last dose)
Time to Maximum Plasma Concentration (Tmax) of SAR441344
Blood samples were collected at the specified timepoints for the assessment of tmax. tmax was assessed by a Bayesian approach using the population PK model.
Time frame: After dose on Day 1 (first dose) and Weeks 8 (IV arm) and 10 (SC arm) (last dose)
Area Under the Curve Over the Dosing Interval (AUC0-tau) of SAR441344
Blood samples were collected at the specified timepoints for the assessment of AUC0-tau. AUC0-tau was assessed by a Bayesian approach using the population PK model.
Time frame: After dose on Day 1 (first dose) and Weeks 8 (IV arm) and 10 (SC arm) (last dose)
The study was conducted at 38 centers in 10 countries. A total of 176 participants were screened from 07 June 2021 to 08 June 2022, of which 47 were screen failures. Screen failures were mainly due to not meeting the eligibility criteria. Primary results are presented up to primary completion date (PCD) of 21 September 2022.
| Milestone | SC Placebo | IV Placebo | SC SAR441344 300 mg | IV SAR441344 1200 mg |
|---|---|---|---|---|
| Started | 14 | 12 | 51 | 52 |
| Completed | 14 | 12 | 49 | 50 |
| Not completed | 0 | 0 | 2 | 2 |
| Withdrew: Adverse event: related to coronavirus disease 2019 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Emergency situation due to war in ukraine | 0 | 0 | 0 | 2 |
| Milestone | SC Placebo | IV Placebo | SC SAR441344 300 mg | IV SAR441344 1200 mg |
|---|---|---|---|---|
| Started | 0 | 0 | 63 | 62 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 63 | 62 |
| Withdrew: Ongoing at the time of pcd | 0 | 0 | 63 | 62 |
Cranial (brain) MRI was performed to identify number of new GdE T1-hyperintense lesions at Week 12 relative to Week 8 MRI. Central review was used to identify new GdE T1 lesions not present at the previous MRI scans.
| number of new GdE T1 lesions per month | Placebo | SC SAR441344 300 mg | IV SAR441344 1200 mg |
|---|---|---|---|
| Mean Number of New Gadolinium (Gd)-Enhancing T1--Hyperintense (GdE T1) Lesions at Week 12 Relative to Week 8 as Measured by Brain Magnetic Resonance Imaging (MRI) | 1.4 (0.62 to 2.98) | 0.3 (0.13 to 0.59) | 0.2 (0.06 to 0.39) |
Cranial (brain) MRI was performed to identify number of new or enlarging T2 lesions at Week 12 relative to Week 8.
| number of new or enlarging T2 lesions | Placebo | SC SAR441344 300 mg | IV SAR441344 1200 mg |
|---|---|---|---|
| Mean Number of New or Enlarging T2 Lesions at Week 12 Relative to Week 8 | 3.8 ± 6.2 | 0.6 ± 1.8 | 0.3 ± 0.7 |
Cranial (brain) MRI was performed to identify total number of GdE T1 lesions at Week 12.
| number of GdE T1 lesions | Placebo | SC SAR441344 300 mg | IV SAR441344 1200 mg |
|---|---|---|---|
| Mean Total Number of GdE T1 Lesions at Week 12 | 3.7 ± 7.4 | 0.5 ± 1.5 | 0.2 ± 0.5 |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.
| Participants | SC Placebo | IV Placebo | SC SAR441344 300 mg | IV SAR441344 1200 mg |
|---|---|---|---|---|
| TEAEs | 5 | 3 | 23 | 15 |
| TESAEs | 0 | 0 | 0 | 0 |
Blood samples were collected at specified timepoints to assess the presence of ADAs against SAR441344. Treatment-emergent ADA was defined as at least 1 treatment-induced/boosted ADA. Treatment-induced ADA was defined as ADA that developed during the TE period and without pre-existing ADA (including participants without pre-treatment samples). Treatment-boosted ADA was defined as pre-existing ADA that was boosted during the TE period to a significant higher titer than the baseline. Number of participants with treatment-emergent ADA are presented.
| Participants | SC Placebo | IV Placebo | SC SAR441344 300 mg | IV SAR441344 1200 mg |
|---|---|---|---|---|
| Double-Blind Period: Number of Participant With Anti-Drug Antibodies (ADAs) Against SAR441344 | 0 | 0 | 3 | 0 |
Blood samples were collected at the specified timepoints for the assessment of Cmax. Cmax was assessed by a Bayesian approach using the population pharmacokinetic (PK) model.
| microgram per milliliter (mcg/mL) | SC SAR441344 300 mg | IV SAR441344 1200 mg |
|---|---|---|
| After first dose | 196 ± 34.4 | 623 ± 125 |
| After last dose | 101 ± 20.9 | 580 ± 116 |
Blood samples were collected at the specified timepoints for the assessment of tmax. tmax was assessed by a Bayesian approach using the population PK model.
| hour | SC SAR441344 300 mg | IV SAR441344 1200 mg |
|---|---|---|
| After first dose | 1.5 (1 to 1.5) | 1.5 (1 to 2) |
| After last dose | 97.2 (79 to 123) | 1.38 (0.92 to 1.77) |
Blood samples were collected at the specified timepoints for the assessment of AUC0-tau. AUC0-tau was assessed by a Bayesian approach using the population PK model.
| mcg*hour/mL | SC SAR441344 300 mg | IV SAR441344 1200 mg |
|---|---|---|
| After first dose | 32800 ± 3560 | 157000 ± 23900 |
| After last dose | 31900 ± 7580 | 190000 ± 39400 |
Collected over AEs and SAEs were collected from first dose of study drug (Day 1) up to 12 weeks (DB TE period). All-cause mortality (deaths) were collected from screening (Week -4) up to PCD of 21 September 2022, approximately up to 67 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SC Placebo | 0/14 (0%) | 0/14 (0%) | 5/14 (35.7%) |
| IV Placebo | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| SC SAR441344 300 mg | 0/51 (0%) | 0/51 (0%) | 9/51 (17.6%) |
| IV SAR441344 1200 mg | 0/52 (0%) | 0/52 (0%) | 6/52 (11.5%) |
| Event | SC Placebo | IV Placebo | SC SAR441344 300 mg | IV SAR441344 1200 mg |
|---|---|---|---|---|
| Covid-19Infections and infestations | 0/14 | 0/12 | 5/51 | 0/52 |
| LeukopeniaBlood and lymphatic system disorders | 0/14 | 1/12 | 0/51 | 1/52 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/14 | 1/12 | 0/51 | 0/52 |
| ErythemaSkin and subcutaneous tissue disorders | 0/14 | 1/12 | 0/51 | 0/52 |
| PruritusSkin and subcutaneous tissue disorders | 0/14 | 1/12 | 0/51 | 0/52 |
| Injection Site PainGeneral disorders | 0/14 | 1/12 | 1/51 | 1/52 |
| Injury Associated With DeviceGeneral disorders | 0/14 | 1/12 | 0/51 | 0/52 |
| Non-Cardiac Chest PainGeneral disorders | 0/14 | 1/12 | 0/51 | 0/52 |
| PyrexiaGeneral disorders | 0/14 | 1/12 | 0/51 | 0/52 |
| NasopharyngitisInfections and infestations | 1/14 | 0/12 | 2/51 | 2/52 |
The randomized population included all participants from screened population who were allocated to a randomized study drug by interactive response technology regardless of whether the study drug was received.
| Age, Continuous(years) | SC Placebo | IV Placebo | SC SAR441344 300 mg | IV SAR441344 1200 mg | Total |
|---|---|---|---|---|---|
| Mean | 31.6 ± 10.8 | 32.3 ± 7.7 | 38.2 ± 8.9 | 37.3 ± 9.3 | 36.6 ± 9.4 |
| Sex: Female, Male(Participants) | SC Placebo | IV Placebo | SC SAR441344 300 mg | IV SAR441344 1200 mg | Total |
|---|---|---|---|---|---|
| Female | 10 | 7 | 31 | 37 | 85 |
| Male | 4 | 5 | 20 | 15 | 44 |
| Race/Ethnicity, Customized(Participants) | SC Placebo | IV Placebo | SC SAR441344 300 mg | IV SAR441344 1200 mg | Total |
|---|---|---|---|---|---|
| Black or African American | 0 | 0 | 1 | 0 | 1 |
| White | 14 | 12 | 50 | 52 | 128 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jun 2021 to primary completion in Sep 2022, 15 months.
Results were first posted in Sep 2025, 3 years after primary completion. A results delay was requested in Sep 2023.
Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 15 months is below that.
Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Frexalimab